

What Advertisers Need to Know About Health Data Privacy Regulation


August 13, 2024

Aaron Burstein, Partner
Privacy and Information Security

Chris Tarbell, Special Counsel
Privacy and Information Security



Our Roadmap for Today



Setting the Scene

- **16 states** have enacted laws requiring opt-in consent to process health data
- “Consumer Health Data” laws in WA and NV (effective 3/31/24) require consent or authorization to use health data for advertising
 - What have we seen (or not seen) since then?
- FTC is sharply focused on health data
 - Cerebral, Monument, Premom, BetterHelp, and other enforcement actions
 - [“Baker’s Dozen”](#) [“Hashing Doesn’t Make Your Data Anonymous”](#) blog posts

What is Health Data?

- Washington’s “My Health My Data Act” (MHMDA) vs. other state laws
- FTC trends
 - Health information is “anything that conveys information – or enables an inference – about a consumer’s health”
 - Includes presence at a sensitive health-related *location* (e.g., reproductive health clinic)
- Challenges to broad definitions of health data
 - *American Hospital Association v. Becerra*
 - *FTC v. Kochava*: district court held that invasion of privacy and potential discrimination, stigma, etc. are forms of “substantial injury”



What is Health Data?

- No uniform definition across the legal landscape.
- Approach to identifying health data for any particular company needs to be tailored to risk tolerance, operational capabilities, scalability, ease of use, and business priorities.
- Key Questions:
 - What is the data (e.g., personal data, data type (e.g., employee, consumer))?
 - Where does the data come from (e.g., geography, source (e.g., survey, website, third party))?
 - What does the data reveal or relate to (e.g., health condition, sensitive health matter, health services)?
 - How is the data being used (e.g., make an inference, to identify, to collect and analyze)
 - Are there any objective factors to consider (e.g., contracts, HSA/FSA, public statements)?


Key Compliance Scenarios

- Website data collection + health data policy
- Personalization and other internal uses
- Audience creation with first-party data. Is the audience health data to:
 - The advertiser?
 - Adtech vendors?
 - The publisher that displays an ad?

Key Considerations for Advertisers


- First-party data ≠ carte blanche for advertising
 - Regulators will focus on consumers' expectations
 - Notices, choices must be consistent with all advertising use cases
- Partner diligence is a must
 - Targeting: Are segment definitions/descriptions sensitive? Are they built on sensitive data?
 - Measurement: How will measurement be performed? What data will partners collect? What data will they provide to you?

The Allure of Deidentification




Health Data Deidentification: The Basics

Step 1: Covered entity




Step 2: Business/controller



Key considerations

- Breadth of HIPAA exemption: CCPA (data-level) vs. other state laws (entity-level)
- Under § 1798.146, CCPA does not apply to information that is:
 - Deidentified in accordance with HIPAA and
 - “Derived from” PHI originally from a covered entity or business associate
- Does data **remain** deidentified throughout the lifecycle (step 2 and beyond)?

Common Deidentification Scenarios



Key considerations

- What is the business/controller's use case?
- Which use cases are covered by deidentification analysis?
- Which identifiers are used?
- Where does matching occur?

FAQs

Can I use my current consent banner to get consent for health data?

What do I do if I get a demand letter or a draft complaint?

How do I post my notice?

Is there any hope for federal privacy legislation?

What are enforcement priorities? Who are likely targets?

How do I keep data classifications up to date?

How do I monitor for new risks?

Key Takeaways

- ✓ Focus on the fundamentals: transparency, clear consent, data security
- ✓ Consider an entity's role and use case details to identify health data
- ✓ Map (potential) health data disclosures to third parties
- ✓ Elevate health data in due diligence of data vendors and other partners
- ✓ Consider a broad range of health data-related harms
- ✓ Relief in sensitive data cases is extensive

QUESTIONS

THANK YOU!



Aaron Burstein, Partner
aburstein@kelleydrye.com



Chris Tarbell, Special Counsel
ctarbell@kelleydrye.com